Tag Archives: rare diseases

AstraZeneca Teams Up with Cellectis to Accelerate Gene Therapy Development

(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release

Sanofi launches more impactful Corporate Social Responsibility (CSR) strategy

Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines (PRESS RELEASE) PARIS, 7-Apr-2021 — … Read the full press release

Rare disease: Enhertu of AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release

Shire: U.S. FDA approval makes CINRYZE® available to help prevent angioedema attacks in children with hereditary angioedema

CINRYZE is the first and only therapy indicated in the U.S. to help prevent angioedema attacks in pediatric patients with hereditary angioedema (HAE) as young as 6 Shire is the only drug developer to complete a pediatric study for the … Read the full press release

U.S. FDA approval for Shire’s first submission for its new plasma manufacturing facility near Covington, Georgia

New facility will add 30% capacity to Shire’s internal plasma manufacturing network once fully operational Expanded capacity supports continued strong growth of Shire’s leading immunoglobulin portfolio and further strengthens ability to deliver complex therapies for rare immune-mediated conditions DUBLIN, 25-Jun-2018 … Read the full press release

Alliance Life Sciences is a Sponsor at World Pharma Pricing and Market Access Congress 2018, Showcasing Data and Technology Solutions

World Pharma Pricing and Market Access Congress 2018 Business Design Centre, London United Kingdom SOMERSET, N.J. / LONDON, UK, 19-Mar-2018 — /EuropaWire/ — Alliance Life Sciences, a leading global life sciences consulting, pricing data and technology provider, announced that it is … Read the full press release

Sanofi acquires Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders

Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases  Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders  Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release

Shire CMO Howard Mayer, M.D.: no patient is currently being denied access to treatment with Hemlibra

DUBLIN, 16-Jan-2018 — /EuropaWire/ — At Shire, we’ve been committed to the hemophilia community and the lives of every patient afflicted with this disease for more than 70 years. We are very proud of this legacy and take our role as … Read the full press release

Shire: EU approval of ADYNOVI is an important milestone in our continued commitment to provide new treatment options for patients with hemophilia A

Marketing Authorization will enable patient access to ADYNOVI throughout Europe ZUG, 16-Jan-2018 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for ADYNOVI … Read the full press release

200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines

LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release

EURORDIS: Rare diseases are not yet recognised as an international public health priority

BRUSSELS, 18-3-2015 — /EuropaWire/ — The 22nd meeting of the EURORDIS Round Table of Companies recently took place in Brussels on the occasion of Rare Disease Day 2015 and focused on the theme ‘Rare Diseases: Going Global’. This EURORDIS corporate-membership group … Read the full press release

EURORDIS: Participants in over 80 countries join together for better care on the Rare Disease Day 2014

Paris, France, 28-2-2014 — /EuropaWire/ — Today is our day. 28 February 2014. Rare Disease Day 2014. Let the world know! There are many ways you can share the news that Rare Disease Day is TODAY! A multitude of activities and events are already … Read the full press release

Rare Disease Day: Novartis hosts 2nd international conference dedicated to the research of rare and orphan diseases

Company is pleased to host second international conference dedicated to the research of rare and orphan diseases Novartis is engaging in public dialogue to help raise greater awareness of rare diseases and support for patients Company celebrates more than 50 … Read the full press release

EU Health Prize for Journalists seeks to reward excellence in health journalism, now open to 28 European countries

Brussels, 14-6-2013 — /europawire.eu/ — Today, the virtual doors swing open to journalists from across the EU wishing to participate in the annual EU Health Prize for Journalists. Winners can pick up EU-wide recognition and cash prizes for excellence in health journalism, … Read the full press release